EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
Rhea-AI Summary
EUDA (NASDAQ: EUDA) announced that Shenzhen Inno Immune received approval under the 2025 Shenzhen Key Industry R&D Program for a TCR-T therapy project running Jan 1, 2026–Dec 31, 2028. The Bureau may provide funding of up to approximately US$434,688. EUDA holds non-exclusive rights to market and sell selected Shenzhen Inno immunotherapies in Malaysia via subsidiary CK Health Plus Sdn Bhd, with treatments to be conducted in China. The project targets solid tumors using AI-driven antigen screening, enhanced TCR engineering, and exploratory clinical studies in collaboration with Shenzhen research institutions and Shenzhen People’s Hospital.
Positive
- Project approved under a government-run Shenzhen Key Industry R&D Program
- Potential funding of up to US$434,688 to support TCR-T development
- Non-exclusive distribution rights to market Shenzhen Inno immunotherapies in Malaysia
- Collaborations with Shenzhen Bay Laboratory and Shenzhen Institutes of Advanced Technology
Negative
- Funding capped at approximately US$434,688, a limited R&D subsidy
- Distribution is non-exclusive, limiting market control in Malaysia
- Treatments are conducted in China, which may limit onshore patient access in Malaysia
News Market Reaction – EUDA
In the Apr 28 session, EUDA declined 6.69%, reflecting a notable negative market reaction. Argus tracked a peak move of +101.0% during that session. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Nasdaq MVLS notice | Negative | +21.1% | Nasdaq notified EUDA it failed the $35M market value listing requirement. |
| Mar 19 | Reverse stock split | Negative | -15.2% | Board approved a 1-for-20 reverse split to combine outstanding ordinary shares. |
| Mar 04 | Warrant repurchase | Positive | -2.7% | Company paid US$125,000 to cancel a warrant for up to 2,000,000 shares. |
| Jan 15 | Warrant amendment | Negative | -4.2% | Reduced warrant exercise price to US$2.00 and lowered forced-exercise trigger level. |
| Jan 13 | Convertible loan deal | Positive | -13.9% | EUDA agreed to invest up to RMB 6 million via a convertible loan in Shenzhen Inno. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw negative or mixed corporate actions met with selling, while regulatory or balance-sheet overhang items sometimes produced divergent price strength.
Over the last several months, EUDA issued multiple capital-structure and financing updates, including warrant amendments, a convertible loan to Shenzhen Inno, and a Nasdaq minimum market value notice. Several items, such as the Streeterville warrant amendments and November 2025 debt-related filings, highlighted dilution and balance-sheet restructuring. The January 2026 repurchase and cancellation of a warrant removed potential issuance of up to 2,000,000 shares. Today’s announcement continues the Shenzhen Inno relationship, now emphasizing government-supported TCR-T development that could complement EUDA’s existing China-focused regenerative and cellular therapy initiatives.
Key Terms
tcr-t cell therapies medical
solid tumors medical
hla-restricted epitopes medical
cancer-testis antigens medical
ai-driven screening technical
t-cell exhaustion medical
tumor microenvironment medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of cellular therapies in China, has received official approval under the 2025 Shenzhen Key Industry R&D Program.
The Shenzhen Key Industry R&D Program is a government-run initiative designed to support critical technological innovation and industrial development. The approved project is scheduled to be implemented from January 1, 2026, to December 31, 2028, under the supervision of the Shenzhen Science and Technology Innovation Bureau (the “Bureau”). Following this approval, it is expected that the Bureau may provide funding of up to approximately US
Pursuant to a non-exclusive distribution arrangement, EUDA holds the rights to market and sell selected immunotherapies provided by Shenzhen Inno to customers in Malaysia through its subsidiary CK Health Plus Sdn Bhd, with treatments conducted in China.
Shenzhen Inno’s Project Highlights & Scientific Focus
Shenzhen Inno’s project focuses on the development of TCR-T cell therapies targeting solid tumors, an area of oncology that remains challenging due to tumor heterogeneity and immune resistance.
• Broad Target Coverage
Development of HLA-restricted epitopes targeting cancer-testis antigens with high expression across multiple tumor types, with an initial focus on epitopes prevalent within the Chinese population.
• AI-Driven Antigen Screening Platform
Utilization of high-throughput, AI-driven screening technologies to identify optimized TCR candidates, in collaboration with leading research institutions including Shenzhen Bay Laboratory and the Shenzhen Institutes of Advanced Technology under the Chinese Academy of Sciences.
• Enhanced Cellular Engineering
Engineering of TCR-T cells designed to address key therapeutic limitations such as T-cell exhaustion and limited persistence within the tumor microenvironment, with the objective of improving durability and efficacy.
• Integrated Research and Clinical Framework
Collaboration with Shenzhen People’s Hospital to conduct exploratory clinical studies evaluating safety and efficacy, alongside the development of standardized yet adaptable manufacturing processes for advanced cellular therapies.
Strategic Relevance to EUDA
The approval of this project under a government-led program reflects continued progress in cellular immunotherapy development and aligns with EUDA’s strategy to expand access to advanced treatment modalities through its commercial channels. This development provides EUDA with continued exposure to next-generation T-cell therapies within its existing distribution scope. Through its distribution framework, EUDA facilitates the delivery of science-driven healthcare solutions to its customers while maintaining a commercially focused approach to advanced therapies.
Mr. Alfred Lim, Chief Executive Officer of EUDA, commented:
“The approval of this project reflects ongoing progress in advanced cellular therapy research. Developments in areas such as TCR-T therapy continue to expand the scope of future treatment possibilities, and EUDA remains focused on identifying opportunities to bring clinically relevant innovations to our customers.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than
Forward-Looking Statements
Certain statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that refer to expectations or other characterizations of future events, circumstances or results are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The factors may include, but not be limited to, factors related to the Company’s anticipated growth strategies, future business development, ability to develop new products, expand to other related industries or markets, and other information detailed from time to time in the filings and future filings with the United States Securities and Exchange Commission. The views expressed are those of management and are based on currently available information. Estimates and projections contained herein have been prepared by management and involve significant elements of subjective judgment and analysis and are based on certain assumptions. No representation nor warranty, expressed or implied, is made as to the accuracy or completeness of the information contained in this document, and nothing contained herein is, or shall be relied upon, as a promise or representation, whether as to the past or the future. You are cautioned not to place undue reliance on these forward-looking statements.
This press release is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company’s stock. This press release is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice. Except for ongoing obligations of the Company to disclose material information under the federal securities laws, the Company does not undertake any obligation to release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
Christensen Advisory
Christian Arnell
Phone: + 852 9040 0621
Email: christian.arnell@christensencomms.com
